New drug combo aims to shrink bladder tumors before surgery
NCT ID NCT06511648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests erdafitinib alone or with cetrelimab before surgery in 90 people with muscle-invasive bladder cancer that has specific gene changes (FGFR). Participants cannot take standard cisplatin chemotherapy. The goal is to see if the drugs can eliminate or shrink the tumor before removal, improving outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erdafitinib and cetrelimab
- What this could lead to
- If successful, this could offer a new treatment option before surgery for people with a specific type of bladder cancer who cannot take standard chemotherapy.
- What could go wrong
- This is an early phase 2 trial with only 90 participants, so results are not yet proven. The drugs may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
A.O. Ordine Mauriziano, Ospedale Umberto I
WITHDRAWNTuri, 10128, Italy
-
Barts Health NHS Trust
RECRUITINGLondon, W6 8JA, United Kingdom
-
CLCC Jean Perrin
RECRUITINGClermont-Ferrand, 63011, France
-
CLCC Léon Bérard
WITHDRAWNLyon, 69008, France
-
Charing Cross Hospital
RECRUITINGLondon, United Kingdom
-
Complexo Hospitalario Universitario A Coruña
RECRUITINGA Coruña, Galicia, 15006, Spain
-
Fundación Instituto Valenciano De Oncología
RECRUITINGValencia, 46009, Spain
-
Hospital Clínic De Barcelona
RECRUITINGBarcelona, Catalonia, 08036, Spain
-
Hospital Clínico Universitario De Valladolid
RECRUITINGValladolid, 47003, Spain
-
Hospital De Sabadell (Parc Taulí)
RECRUITINGBarcelona, Catalonia, 08208, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Lucus Augusti
RECRUITINGLugo, Galicia, 27003, Spain
-
Hospital Universitario Miguel Servet
RECRUITINGZaragoza, 50009, Spain
-
Hospital Universitario de Toledo
RECRUITINGToledo, 45007, Spain
-
ICO l' Hospitalet
NOT_YET_RECRUITINGBarcelona, 08908, Spain
-
IRCCS San Raffaele Hospital and Scientific Institute
RECRUITINGMilan, 20132, Italy
-
IUCT
RECRUITINGToulouse, 31059, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Institut Mutualiste Montsouris
RECRUITINGParis, 75014, France
-
Ospedale Molinette
RECRUITINGTurin, 10126, Italy
-
Sheffield Teaching Hospitals NHS Foundation Trust
RECRUITINGSheffield, S10 2SJ, United Kingdom
-
The Royal Marsden NHS Foundation Trust
RECRUITINGLondon, SW3 6JJ, United Kingdom
-
University Hospitals of Morecambe Bay NHS Foundation Trust
WITHDRAWNLancaster, LA1 4RP, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Can a special PET scan see bladder cancer more clearly?
- Bladder cancer surgery: what happens after the bladder is removed?
- Lab-Grown tumor clusters guide tailored bladder cancer therapy
- Experimental immunotherapy targets tough urinary cancers